Background: In the COMPASS trial, the combination of acetylsalicylic acid (ASA) plus 2.5 mg
rivaroxaban twice daily (dual-pathway inhibition, DPI) has been shown to be superior to ASA …

Although acetylsalicylic acid is of proven benefit for secondary prevention in patients with
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …

Aims To determine the characteristics of patients with coronary artery disease (CAD),
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …

Despite available effective guideline-based preventive therapies, patients with vascular
diseases remain at high-risk of recurrent ischaemic events. Novel therapeutic strategies are …

Aims Guidelines recommend extended dual pathway inhibition (DPI) with aspirin and
rivaroxaban in patients with chronic coronary syndrome (CCS) at high ischaemic risk. The …

Most ischemic events in patients with coronary artery disease, peripheral artery disease, or
cerebrovascular disease result from thrombosis or embolism arising from disrupted …

Aims Low-dose (LD) direct oral anticoagulants (DOACs) in adjunct to antiplatelet therapy,
known as dual-pathway inhibition (DPI), have been tested to prevent ischaemic events in …

Introduction Cardiovascular disease is the leading cause of morbidity and mortality in adults
in western nations. In the last decades, tremendous research has been conducted in the …

Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …

Atherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease
(CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with …